The European Agency for the Evaluation of Medicines, which is equivalent to the U.S.' FDA, is planning to ask drug companies to submit data on their products, including those that failed to gain regulatory approval. But the drug industry says the planned disclosure law could mar commercial prospects.

Related Summaries